Autologous CAR-T
iconArrow
Product Candidate1
Technology
Target
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA

Zevor-cel (CT053)3

More+
Technology:

Conventional

Target:
BCMA
BCMA
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
R/R MM
LUMMICAR 1 (China)
launched
R/R MM
LUMMICAR 2 (US, Canada)

Satri-cel (CT041)

More+
Technology:

Conventional

Target:
Claudin18.2
Claudin18.2
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
GC/GEJ 
ST-01 (China)
GC/PC
ST-02 (US, Canada)
PC (adjuvant)
ST-05 (China)
GC/GEJ, PC, etc.
IIT (China)
GC/GEJ (adjuvant)
IIT (China)

CT071

More+
Technology:

CARcelerate®

Target:
GPRC5D
GPRC5D
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
R/R MM,R/R pPCL
(US)
R/R MM,R/R PCL
IIT(China)
NDMM
IIT(China)

CT011

More+
Technology:

Conventional

Target:
GPC3
GPC3
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
HCC (adjuvant)
(China)
Allogeneic CAR-T
iconArrow
Product Candidate1
Technology
Target
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA

CT05904

More+
Technology:

THANK-uCAR®

Target:
BCMA
BCMA
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
R/R MM, R/R PCL
IIT(China)

CT059X

More+
Technology:

THANK-uCAR®

Target:
BCMA
BCMA
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
R/R MM, R/R PCL
IIT (China)

KJ-C2219

More+
Technology:

THANK-uCAR®

Target:
CD19/CD20
CD19/CD20
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
Hematologic malignancies and autoimmune diseases
IIT (China)

KJ-C2320

More+
Technology:

THANK-uCAR®

Target:
CD38
CD38
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
AML
IIT (China)

KJ-C2114

More+
Technology:

THANK-uCAR®

Target:
Undisclosed
Undisclosed
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
Solid tumors

KJ-C2526

More+
Technology:

THANK-uCAR®

Target:
NKG2DL
NKG2DL
Indication
Pre-clinical
Phase I
Phase II/III2
BLA/NDA
AML, other malignancies, senescence
for hematologic malignancies
for solid tumors

R/R MM: relapsed/refractory multiple myeloma; GC: gastric cancer; GEJ: gastroesophageal junction cancer; PC: pancreatic cancer; HCC: hepatocellular carcinoma; R/R pPCL: relapsed/refractory primary plasma cell leukemia; NDMM: newly diagnosed multiple myeloma; AML: acute my eloid leukemia

1 All product candidates are self-developed with global rights

2 Phase II trials of some indications are pivotal studies

3 Core Product Candidate. Commercial rights in mainland China have been granted to Huadong Medicine (SZ: 000963). Rights in the South Korean market have been licensed out to HK Inno.N (KOSDAQ: 195940)

4 CT0590 enrollment finished